Although some of these symptoms were seen in our patients undergoing treatment with DDD CT (Herxheimer reactions, anemia, mild elevations in methemoglobin), adverse side effects were minimized by ruling out G-6-P-D deficiency; using high-dose folic acid therapy with folinic acid (50–75 mg/day) and L-methyl folate (30–45 mg/day); and administering glutathione precursors (NAC 600 mg BID), alpha lipoic acid (ALA, 600 mg BID), and glutathione (GSH, 1000 mg BID) with methylene blue 50 mg BID as needed. Here, HBG2 is linked to anemia (phenotype).